| Today’s Big NewsApr 5, 2024 |
| By Fraiser Kansteiner Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S. and adopt a different way of marketing its Humira biosimilar. |
|
|
|
By Max Bayer Sanofi is laying off staff around the globe following a 'full pipeline reprioritization,' according to an email from R&D chief Houman Ashrafian to staff. The communication, obtained by Fierce Biotech, refer to a large-scale restructuring to afford late-stage drug development. |
By Conor Hale J&J MedTech sees Shockwave’s devices for cracking open calcified arteries as the ticket to its 13th billion-dollar platform. |
By Ben Adams It’s as you were at the top of the pharma drug ad spending list in March as AbbVie’s immunology blockbusters Rinvoq and Skyrizi stay first and second, respectively. |
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now!
|
|
By Angus Liu After a short period of doubt, the FDA has followed the opinion of its advisers and moved Bristol Myers’ CAR-T therapy Abecma into the earlier treatment of multiple myeloma. The new nod also comes with an updated boxed warning and a wider dosing range. |
By James Waldron Contineum Therapeutics has lowered its IPO expectations as the Johnson & Johnson-partnered biotech prepares to make the jump to the public markets this morning. |
By Angus Liu AstraZeneca's Imfinzi has delivered positive clinical data in another type of lung cancer, building on the immunotherapy’s existing FDA clearance in stage 3 non-small cell lung cancer and extensive-stage small cell lung cancer. |
By Andrea Park As it works toward improving the diversity of its workforce, Bayer took a moment this week to celebrate some of the diverse voices already on board—and its own efforts to uphold their rights. |
By Angus Liu After two delays spanning over a year, Novartis is finally gearing up for a high-stakes FDA application to expand the radiotherapy Pluvicto into earlier treatment of prostate cancer. But will the FDA bite? |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged. |
|
|---|
|
|
|
Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this discussion on-demand to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now.
|
|
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
